- Denali Therapeutics (NASDAQ:DNLI) has priced its initial public offering at $18/share, the midpoint of its expected range.
- With 13,888,888 shares in the offering, gross proceeds come to $250M. Underwriters have a 30-day option to buy up to 2,083,333 more shares at the IPO price.
- Shares are expected to begin trading on Nasdaq tomorrow, with the offering closing Dec. 12.
- Goldman Sachs, Morgan Stanley and J.P. Morgan are joint book-runners.
Denali Therapeutics prices IPO at $18/share
Recommended For You
More Trending News
About DNLI Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
DNLI | - | - |
Denali Therapeutics Inc. |